OtoImmune develops precision immunology solutions that enable detailed profiling of immune responses for research and clinical applications. Their platform leverages proprietary mOI™ and mOI Health™ technologies to deliver high‑resolution immune data, helping scientists and clinicians better understand disease mechanisms and personalize treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers and clinicians lack high‑resolution, scalable tools to profile immune responses, making it difficult to select optimal immunotherapies and monitor treatment effects in a personalized manner.
Solution
OtoImmune offers the proprietary mOI™ platform, a precision immunology suite that delivers detailed immune profiling through multiplexed biomarker analytics. The platform supports both diagnostic and therapeutic workflows, enabling users to identify relevant immune signatures, stratify patients, and track response to immune‑based treatments. Integrated assay technology provides reproducible results with scalable throughput, facilitating rapid data generation for research and clinical decision‑making. By coupling the mOI™ platform with the mOI Health™ and OtoImmune™ product lines, the company supplies end‑to‑end solutions that accelerate immune‑therapy development and support personalized treatment strategies.
Target Audience
Primary customers are biomedical researchers, pharmaceutical developers, and clinical teams focused on immunotherapy development and personalized immune monitoring.
Features
- Multiplexed assay panels that quantify a broad range of immune biomarkers in a single run
- High‑resolution immune profiling with quantitative readouts for cell subsets, cytokines, and checkpoint molecules
- Scalable workflow compatible with standard laboratory equipment and automated processing
- Integrated data analytics suite that translates raw assay data into actionable immune signatures
- Modular product ecosystem (mOI Health™ and OtoImmune™) for both research applications and clinical diagnostics